Abstract
Purpose
To retrospectively review outcomes in patients treated for colorectal liver metastases with DEBIRI.
Materials and Methods
A retrospective analysis of patients with CRLM treated with DEBIRI was performed between 2008 and 2017 between two tertiary centres. Outcome parameters were overall survival and hepatic progression-free survival, as well as safety. Subgroup analyses were performed to assess the impact on outcomes of hepatic tumour burden at time of treatment, the presence of extrahepatic disease, prior systemic chemotherapy and the prior administration of systemic irinotecan-containing chemotherapy.
Results
Fifty-three patients received 125 treatments with DEBIRI over the study period. Median age of patients was 71 (range 41–88). Patients previously received a median of 1 line of chemotherapy (range 1–5). Median number of DEBIRI treatments was 2 (range 1–6). The median survival from first treatment was 14.5 months (range 1–107). Median hepatic progression-free survival was 5 months (0–86.5 months). The presence of extrahepatic disease (seen in 45% of patients) correlated with lower OS. Prolonged OS was seen in patients who received previous ablation and systemic chemotherapy. Technical success rate was found to be 99%. Post-procedural complication rate was 6%.
Conclusion
Our findings add to the growing body of literature to support the safety profile of DEBIRI in the treatment of CRLM. Further studies will be necessary to help establish the optimum berth of DEBIRI in the treatment algorithm for colorectal liver metastases.
Similar content being viewed by others
References
Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr. Accessed 1 July 2018.
Gruber-Rouh T, Naguib N, Eichler K, et al. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period. Int J Cancer. 2014;134(5):1225–31. https://doi.org/10.1002/ijc.28443.
Fong Y, Blumgart LH. Hepatic colorectal metastasis: current status of surgical therapy. Oncology. 1998;12:1489–503.
Aliberti C, Tilli M, Benea G, Fiorentini G. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res. 2006;26:3793–5.
Akinwande O, Scoggins C, Martin RC. Early experience with 70–150 μm irinotecan drug-eluting beads (M1-DEBIRI) for the treatment of unresectable hepatic colorectal metastases. Anticancer Res. 2016;36(7):3413–8.
Martin R, Scoggins C, Schreeder M, et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015;121(20):3649–58.
Lencioni R, Aliberti C, de Baere T, Garcia-Monaco R, Narayanan G, O’Grady E, Rilling WS, Walker D, Martin RC. Transarterial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: technical recommendations. J Vasc Interv Radiol. 2014;25(3):365–9. https://doi.org/10.1016/j.jvir.2013.11.027.
Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32(4):1387–95.
Stutz M, Mamo A, Valenti D, et al. Real-life report on chemoembolization using DEBIRI for liver metastases from colorectal cancer. Gastroenterol Res Pract. 2015;2015:715102. https://doi.org/10.1155/2015/715102.
Huppert P, Wenzel T, Wietholtz H. Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population. Cardiovasc Intervent Radiol. 2014;37(1):154–64. https://doi.org/10.1007/s00270-013-0632-0.
Martin R, Robbins K, Tomalty D, et al. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol. 2009;7:80. https://doi.org/10.1186/1477-7819-7-80.
Bhutiani N, Akinwande O, Martin R. Efficacy and toxicity of hepatic intra-arterial drug-eluting (Irinotecan) Bead (DEBIRI) therapy in irinotecan-refractory unresectable colorectal liver metastases. World J Surg. 2016;40(5):1178–90. https://doi.org/10.1007/s00268-015-3386-9.
Akinwande O, Philips P, Duras P, Pluntke S, Scoggins C, Martin R. Small versus large-sized drug-eluting beads (DEBIRI) for the treatment of hepatic colorectal metastases: a propensity score matching analysis. Cardiovasc Intervent Radiol. 2015;38(2):361–71. https://doi.org/10.1007/s00270-014-1011-1.
Young S, D’Souza D, Flanagan S, et al. Review of the clinical evidence for the use of DEBIRI in the treatment of colorectal metastatic disease. Cardiovasc Intervent Radiol. 2017;40:496. https://doi.org/10.1007/s00270-016-1537-5.
Liu D, Thakor A, Baerlocher M, Alshammari M, Lim H, et al. A review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases: principles and proof. Future Oncol. 2015;11(9):1421–8. https://doi.org/10.2217/fon.15.3.
Richardson A, Laurence J, Lam V. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. J Vasc Interv Radiol. 2013;24(8):1209–17. https://doi.org/10.1016/j.jvir.2013.05.055.
Fiorentini G, Aliberti C, Turrisi G, et al. Intra-arterial hepatic chemoembolisation of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase III clinical study. Vivo. 2007;21(1085):1092.
Watchmaker J, Lipnik A, Fritsche M, Baker J, Mouli S, Geevarghese S, Banovac F, Omary R, Brown D. Are prophylactic antibiotics necessary prior to transarterial chemoembolization for hepatocellular carcinoma in patients with native biliary anatomy? J Surg Oncol. 2018;117(6):1312–7. https://doi.org/10.1002/jso.24993.
Woo S, Chung J, Hur S, Joo S, Kim H, Jae H, Park J. Liver abscess after transarterial chemoembolization in patients with bilioenteric anastomosis: frequency and risk factors. AJR Am J Roentgenol. 2013;200(6):1370–7. https://doi.org/10.2214/AJR.12.9630.
Spreafico C, Cascella T, Facciorusso A, Sposito C, Rodolfo L, Morosi C, Civelli EM, Vaiani M, Bhoori S, Pellegrinelli A, Marchianò A, Mazzaferro V. Transarterial chemoembolization for hepatocellular carcinoma with a new generation of beads: clinical-radiological outcomes and safety profile. Cardiovasc Intervent Radiol. 2015;38(1):129–34. https://doi.org/10.1007/s00270-014-0907-0.
Deipolyi AR, Oklu R, Al-Ansari S, Zhu A, Goyal L, Ganguli S. Safety and efficacy of 70–150 μm and 100–300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2015;26(4):516–22.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Human and Animal Rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
Informed Consent
For this type of study formal consent is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Ngo, A., von Stempel, C., Corbo, B. et al. Transarterial Chemoembolisation of Colorectal Liver Metastases with Irinotecan-Loaded Beads: A Bi-institutional Analysis of 125 Treatments in 53 Patients. Cardiovasc Intervent Radiol 42, 979–990 (2019). https://doi.org/10.1007/s00270-019-02219-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-019-02219-4